Xvivo Perfusion announced during the morning that the PrimECC study now is fully recruited. The study is performed to increase the clinical documentation for the company’s priming solution, which is used in heart-lung machines during cardiac surgeries. The first publication of the results from the study are to be expected at the end of 2017.